ProteoNic licenses vector technology for antibody manufacturing consortium
ProteoNic BV has announced that Ginkgo Bioworks has licensed its proprietary 2G UNic vector technology for a $22.2 million project funded by the Biomedical Advanced Research and Development Authority (BARDA). The initiative aims to enhance domestic biomanufacturing capabilities for monoclonal antibodies targeting filovirus infections, including Ebola and Sudan Virus.

